Corbenic Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History

Corbenic Partners’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1K	Hold	27	–	–	﹤0.01%	194
2022 Q1	$1K	Hold	27	–	–	﹤0.01%	220
2021 Q4	$2K	Hold	27	–	–	﹤0.01%	249
2021 Q3	$2K	Hold	27	–	–	﹤0.01%	246
2021 Q2	$2K	Hold	27	–	–	﹤0.01%	230
2021 Q1	$2K	Hold	27	–	–	﹤0.01%	221
2020 Q4	$3K	Sell	27 -500	-95%	-$39.8K	﹤0.01%	161
2020 Q3	$34K	Buy	527 +500	+1,852%	+$29.3K	0.02%	76
2020 Q2	$1K	Hold	27	–	–	﹤0.01%	147
2020 Q1	$1K	Buy	+27	New	+$902	﹤0.01%	165

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Corbenic Partners's ARKG Position: Q2 2022 in Review

Corbenic Partners held its ARK Genomic Revolution ETF (ARKG) position steady in Q2 2022 at 27 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #194.

Corbenic Partners first reported a position in ARKG in Q1 2020 and has held it in 10 quarters since. The position peaked at $34K in Q3 2020. 333 funds tracked by Wall St. Rank hold ARKG as of Q2 2022.

Corbenic Partners held 27 shares of ARK Genomic Revolution ETF worth $1K as of Q2 2022.
Corbenic Partners left its ARK Genomic Revolution ETF share count unchanged in Q2 2022.
ARK Genomic Revolution ETF made up ﹤0.01% of Corbenic Partners's portfolio in Q2 2022, its #194 holding.
Corbenic Partners first reported a position in ARK Genomic Revolution ETF in Q1 2020 and has held it in 10 quarters since.
Corbenic Partners's ARK Genomic Revolution ETF position peaked at $34K in Q3 2020.
333 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2022.

Based on Corbenic Partners's 13F filing for Q2 2022, filed 25 Jul 2022.